Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in.
Recursion Pharmaceuticals Inc. (RXRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 37,316,856 | $152,625,940 | +12% | 1.01% |
| 2. | MIC Capital Partners Mubadala Investment | 9,644,032 | $39,444,095 | 8.94% | |
| 3. | Citadel Investment Group Ken Griffin | 4,229,999 | $17,300,696 | +214% | 0% |
| 4. | 1,978,800 | $8,093,292 | +2% | 0% | |
| 5. | 1,965,600 | $8,039,304 | +81% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.82 | 66,822 | $522,354.26 | 12,985,927 | 2023-03-02 | Filing | |
| $7.94 | 48,867 | $388,082.17 | 12,919,105 | 2023-03-01 | Filing | |
| $7.97 | 815 | $6,495.55 | 12,870,238 | 2023-02-28 | Filing | |
| $7.69 | 52,500 | $403,725.00 | 12,869,423 | 2023-02-27 | Filing | |
| $7.64 | 109,118 | $833,552.40 | 12,816,923 | 2023-02-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.12 | 40,000 | $164,800.00 | 913,839 | 2026-02-04 | Filing | |
| $4.20 | 220,000 | $924,000.00 | 6,429,863 | 2026-02-03 | Filing | |
| $4.47 | 40,000 | $178,800.00 | 913,839 | 2026-01-20 | Filing | |
| $4.36 | 220,000 | $959,200.00 | 6,649,863 | 2026-01-06 | Filing | |
| $4.25 | 40,000 | $170,000.00 | 933,839 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 47,187,759 | $192,997,934 | 0% | |
| 2. | 38,866,779 | $158,965,127 | 0% | |
| 3. | 25,333,888 | $103,615,602 | 0% | |
| 4. | 23,774,972 | $97,239,635 | 0.08% | |
| 5. | 13,636,515 | $55,773,346 | 0.36% |
News See All
8 Overlooked Penny Stocks to Invest in
Penny stocks, or stocks trading under $5, often get overlooked due to their volatility and speculative nature.
Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory
We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on r/stocks by Antique-Reference585. In this article, we will summarize the bulls’ thesis on RXRX.
JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best debt-free penny stocks to buy right now.
10 Best Debt-Free Penny Stocks to Buy Right Now
Small-cap companies are crushing it after years of underperformance. In 2025, the Russell 2000 index rose 13% even as focus remained on large-cap stocks amid the artificial intelligence boom.
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates
Recursion extended its winning streak to a fourth day on Wednesday, jumping 6.81 percent to close at $4.86 apiece as investors gobbled up more shares ahead of expected business updates from its participation...
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc.
10 Best High Volume Penny Stocks to Buy
The Russell 2000 index, which represents small-cap companies, outperformed the “Mag 7” stocks over the past month with 1.68% returns compared to the "Mag 7" 1.03% returns.
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX)
On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, with a price objective of $11 instead of $10.
20 Best AI Stocks to Buy According to Analysts
The S&P 500 is on track to finish the year with a gain exceeding 17%, thanks to a 26% boost in technology stocks.
Hedge Fund Resource Center Billionaire Hedge Funds
